Smad4/DPC4 Silencing and Hyperactive Ras Jointly Disrupt Transforming Growth Factor-β Antiproliferative Responses in Colon Cancer Cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Smad4/DPC4 is a tumor suppressor gene frequently mutated or deleted in pancreatic and metastatic colon cancers. Smad4 acts as a cofactor that binds transforming growth factor-beta (TGF-beta) receptor-activated Smad2 and Smad3 generating transcriptional complexes. Using SW480.7 colon carcinoma cells, defective in Smad4 function, we have investigated whether this loss plays a role in the resistance of colon cancer cells to the antiproliferative effects of TGF-beta. SW480.7 cells contain only one Smad4 allele, which we found encodes a wild type protein that is not expressed. We generated SW480.7 cells conditionally expressing Smad4 via an ecdysone-inducible system. Smad4 expression in these cells failed to rescue TGF-beta antiproliferative and gene responses (c-myc down-regulation and induction of p21/Cip1 and plasminogen activator inhibitor-1). SW480.7 cells contain an activated Ki-ras oncogene. Hyperactivation of Ras can inhibit Smad nuclear accumulation by their phosphorylation at mitogen-activated protein kinase sites. Co-transfection into SW480.7 cells of Smad4 together with a Ras phosphorylation-resistant Smad3 (but not with wild type Smad2, Smad3, adenomatous polyposis coli (APC), or TGF-beta type II receptor) restored the TGF-beta antiproliferative response. These results suggest that loss of Smad4 function by both deletion and silencing and inhibition of Smad2/3 function by a hyperactive Ras pathway jointly prevent TGF-beta antiproliferative responses in SW480.7 colon cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Self-citation
Cited by
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
Self-citationTGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Massagué, J., & Chen, Y.-G. (2000) · Genes & Development · doi:10.1101/gad.14.6.627 · Cited by 1,575
Self-citationBhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L., & Moses, H. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.1.27 · Cited by 1,004
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Self-citationTGF- β signaling in cancer – a double-edged sword
Akhurst, R. J., & Derynck, R. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02130-4 · Cited by 756
A Self-Enabling TGFβ Response Coupled to Stress Signaling
Kang, Y., Chen, C.-R., & Massagué, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00109-6 · Cited by 550
Self-citationSignaling of transforming growth factor‐β family members through Smad proteins
Itoh, S., Itoh, F., Goumans, M., & ten Dijke, P. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01828.x · Cited by 529
Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 526
Role of Transforming Growth Factor-beta Signaling in Cancer
de Caestecker, M. P. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.17.1388 · Cited by 522
E2F4/5 and p107 as Smad Cofactors Linking the TGFβ Receptor to c-myc Repression
Chen, C.-R., Kang, Y., Siegel, P. M., & Massagué, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00801-2 · Cited by 487
Self-citationBIERIE, B., & MOSES, H. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.006 · Cited by 477
Regulation of cell proliferation by Smad proteins
Ten Dijke, P., Goumans, M., Itoh, F., & Itoh, S. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10066 · Cited by 450
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
Javelaud, D., & Mauviel, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208928 · Cited by 400
Hayashida, T., de Caestecker, M., & Schnaper, H. W. (2003) · The FASEB Journal · doi:10.1096/fj.03-0037fje · Cited by 361
Chen, C.-R., Kang, Y., & Massagué, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.992 · Cited by 320
Self-citationCrystal Structure of a Phosphorylated Smad2
Wu, J.-W., Hu, M., Chai, J., Seoane, J., Huse, M., Li, C., Rigotti, D. J., Kyin, S., Muir, T. W., Fairman, R., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00421-x · Cited by 301
Self-citationC/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells
Gomis, R. R., Alarcón, C., Nadal, C., Van Poznak, C., & Massagué, J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.019 · Cited by 273
Self-citationSmad4/DPC4-mediated tumor suppression through suppression of angiogenesis
Schwarte-Waldhoff, I., Volpert, O. V., Bouck, N. P., Sipos, B., Hahn, S. A., Klein-Scory, S., Lüttges, J., Klöppel, G., Graeven, U., Eilert-Micus, C., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9624 · Cited by 266
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
de Geus, S. W. L., Eskander, M. F., Kasumova, G. G., Ng, S. C., Kent, T. S., Mancias, J. D., Callery, M. P., Mahadevan, A., & Tseng, J. F. (2017) · Cancer · doi:10.1002/cncr.30856 · Cited by 118
“These findings may in part be explained by the intrinsic radio resistance of pancreatic cancer cells.(10,11) Stereotactic body radiotherapy (SBRT) permits the precise application of high-dose radiation in 1 to 5 fractions to a limited target volume and, therefore, offers a potential advantage in pancreatic cancer beca…”
BackgroundReduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Yan, P., Klingbiel, D., Saridaki, Z., Ceppa, P., Curto, M., McKee, T. A., Roth, A., Tejpar, S., Delorenzi, M., Bosman, F. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0939 · Cited by 78
Metadata
- Authors
- Calonge, M. J., & Massagué, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-11
- Volume
- 274
- Issue
- 47
- Pages
- 33637-33643
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2067656705
- Cited by
- 146
- References
- 5
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.